10770 Federal Register / Vol. 72, No. 46 / Friday, March 9, 2007 / Notices 

combination with irradiated CT26 cells 

enhances tumor regression in another 

mouse model. The investigators found 

that administering the combination of 

agents is more effective than the sum of 

their individual effects. 

Applications: A method of cancer 

combination therapy based on 

immunotherapeutics. 

Development Status: The invention is 

in the clinical stages of development. 

Inventors: Masaki Terabe (NCI) et al. 

Publications: 

1. PCT patent publication WO 2006/ 

089251, August 24, 2006. 

2. M Terabe et al. Transforming 

growth factor-beta production and 

myeloid cells are an effector mechanism 

through which CD1d-restricted T cells 

block cytotoxic T lymphocyte-mediated 

tumor immunosurveillance: abrogation 

prevents tumor recurrence. J Exp Med. 

2003 Dec 1;198(11):1741–1752. 

Patent Status: U.S. Provisional 

Application No. 60/654,329 filed 17 Feb 

2005 (HHS Reference No. E–019–2005/ 

0–US–01); PCT Application No. PCT/ 

US2006/005888 filed 16 Feb 2006 (HHS 

Reference No. E–019–2005/0–PCT–02). 

Licensing Availability: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov 

Arylthioindole Tubulin Polymerization 

Inhibitors and Methods of Treating or 

Preventing Cancer Using Same 

Description of Technology: 

Microtubules are involved in a variety 

of cellular functions including motility, 

division, shape maintenance, and 

intracellular transport. Tubulin is the 

major protein component in 

microtubules, and interference with 

microtubule assembly leads to an 

increase of cells in metaphase arrest. 

Inhibition of microtubule function using 

tubulin targeted agents are widely used 

in the treatment of cancer. 

This invention describes novel 

arylthioindole derivatives, 3- 

arylthioindole-2-carboxylic acid esters 

derivatives, having excellent affinity for 

tubulin and excellent efficacy as 

inhibitors of the growth of MCF–7 breast 

cancer cells. These new chemical 

compounds have the potential to result 

in more effective therapeutics for the 

treatment of neoplastic diseases. 

Applications: Therapeutic for 

proliferative diseases such as cancer. 

Market: 600,000 deaths from cancer 

related diseases estimated in 2006. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Ernest Hamel (NCI) et al. 

Publications: 

1. G De Martino, MC Edler, G La 

Regina, A Coluccia, MC Barbera, D 

Barrow, RI Nicholson, G Chiosis, A 

Brancale, E Hamel, M Artico, R 

Silvestri. New arylthioindoles: potent 

inhibitors of tubulin polymerization. 2. 

Structure-activity relationship and 

molecular modeling studies. J Med 

Chem. 2006 Feb 9;49(3):947–954. 

2. G De Martino, G La Regina, A 

Coluccia, MC Edler, MC Barbera, A 

Brancale, E Wilcox, E Hamel, M Artico, 

R Silvestri. Arylthioindoles, potent 

inhibitors of tubulin polymerization. J 

Med Chem. 2004 Dec 2;47(25):6120–

6123. 

Patent Status: PCT Application No. 

PCT/US2005/035896 filed 05 Oct 2005 

(HHS Reference No. E–323–2004/0–

PCT–02). 

Licensing Availability: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov. 

Dated: March 2, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–4182 Filed 3–8–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Clinical Center; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the NIH 

Advisory Board for Clinical Research. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: NIH Advisory Board 

for Clinical Research. 

Date: March 23, 2007. 

Time: 10 a.m. to 2 p.m. 

Agenda: To discuss progress of activities 

related to research opportunities, training, 

planning and funding in the NIH intramural 

clinical research program. 

Place: National Institutes of Health, 

Building 10, 10 Center Drive, CRC Medical 

Board Room 4–2551, Bethesda, MD 20892. 

Contact Person: Maureen E. Gormley, 

Executive Secretary, Mark O. Hatfield 

Clinical Research Center, National Institutes 

of Health, Building 10, Room 6–2551, 

Bethesda, MD 20892, 301/496–2897. 

This notice is being published less than 15 

days prior to the meeting due to the urgent 

need to meet timing limitations imposed by 

the intramural research review cycle. 

Any interested person may file written 

comments with the committee by forwarding 

the statements to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Dated: March 2, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1099 Filed 3–8–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the President’s Cancer 

Panel, February 12, 2007, 8 a.m. to 

February 12, 2007, 6 p.m., University of 

Mississippi, Medical Center, 2500 North 

State Street, Jackson, MS 39216 which 

was published in the Federal Register 

on January 11, 2007, 72 FR 1335. 

Due to inclement weather, this 

meeting is amended to reschedule the 

closed session on February 12, 2007, 4 

p.m.–6 p.m. to March 8, 2007, 11 a.m.–

1 p.m. as a telephone conference. The 

meeting is closed to the public. 

Dated: March 5, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1109 Filed 3–8–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 


jlentini on PROD1PC65 with NOTICES